Esperion Therapeutics Inc [NASDAQ: ESPR] gained 16.40% on the last trading session, reaching $3.69 price per share at the time.
Esperion Therapeutics Inc represents 239.06 million in outstanding shares, while the company has a total market value of $882.14 million with the latest information. ESPR stock price has been found in the range of $3.28 to $3.77.
If compared to the average trading volume of 6.98M shares, ESPR reached a trading volume of 19156711 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Esperion Therapeutics Inc [ESPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $6.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.62. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Esperion Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on Nov-26-25. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on December 18, 2024, representing the official price target for Esperion Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Cantor Fitzgerald analysts kept a Overweight rating on ESPR stock.
Trading performance analysis for ESPR stock
Esperion Therapeutics Inc [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.39. With this latest performance, ESPR shares gained by 27.24% in over the last four-week period, additionally plugging by 342.08% over the last 6 months – not to mention a rise of 67.73% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 70.70, with the RSI for the last a single of trading hit 0.24, and the three-weeks RSI is set at 0.22 for Esperion Therapeutics Inc [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.81, while it was recorded at 3.14 for the last single week of trading, and 1.79 for the last 200 days.
Esperion Therapeutics Inc [ESPR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc [ESPR] shares currently have an operating margin of -9.67% and a Gross Margin at 58.22%. Esperion Therapeutics Inc’s Net Margin is presently recorded at -34.84%.
Esperion Therapeutics Inc (ESPR) Capital Structure & Debt Analysis
Esperion Therapeutics Inc (ESPR) Efficiency & Liquidity Metrics
Esperion Therapeutics Inc (ESPR) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Esperion Therapeutics Inc. (ESPR) effectively leverages its workforce, generating an average of -$348125.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.15% and a Quick Ratio of 0.76%, indicating strong ability to cover short-term liabilities.
Esperion Therapeutics Inc [ESPR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Esperion Therapeutics Inc posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR.
An analysis of Institutional ownership at Esperion Therapeutics Inc [ESPR]
There are presently around $47.24%, or 47.45%% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS LP with ownership of 16.86 million shares, which is approximately 8.9319%. BLACKROCK INC., holding 13.98 million shares of the stock with an approximate value of $$31.04 million in ESPR stocks shares; and BLACKROCK INC., currently with $$24.01 million in ESPR stock with ownership which is approximately 5.7294%.
